• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

2.445 +0.015 (+0.62%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 Next >
News headline image
INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings
Today 7:00 EDT
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
July 31, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th
July 31, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
July 30, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform
July 20, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
July 15, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
July 09, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion
July 01, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
June 25, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
June 23, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
June 02, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform
May 15, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease
May 14, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point
May 13, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases
May 05, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
April 30, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models
April 16, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
March 24, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
March 19, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
February 23, 2026
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
February 19, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
February 12, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
February 10, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
January 27, 2026
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform
December 05, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients
December 01, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
November 18, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
October 23, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
October 14, 2025
From INmune Bio, Inc.
Via GlobeNewswire
News headline image
INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
September 29, 2025
From INmune Bio, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap